HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project

English version České info

In an observational study, Gabriela Gomez and colleagues report on provision of pre-exposure prophylaxis and antiretroviral treatment for female sex workers in South Africa.

Vyšlo v časopise: HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project. PLoS Med 14(11): e32767. doi:10.1371/journal.pmed.1002444
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002444

Souhrn

In an observational study, Gabriela Gomez and colleagues report on provision of pre-exposure prophylaxis and antiretroviral treatment for female sex workers in South Africa.

Zdroje

1. GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3:e361–87. doi: 10.1016/S2352-3018(16)30087-X 27470028

2. Joint United Nations Programme on HIV and AIDS. Prevention gap report. Geneva: Joint United Nations Programme on HIV and AIDS; 2016 [cited 2017 Oct 20]. Available from: http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf.

3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830–9. doi: 10.1056/NEJMoa1600693 27424812

4. Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. FRAC0105LB: the impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012–2016. 21st International AIDS Conference; 2016 Jul 18–22; Durban, South Africa.

5. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–83. doi: 10.1097/QAD.0000000000001145 27149090

6. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245 22802730

7. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123. doi: 10.1371/journal.pmed.1001123 22110407

8. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056. doi: 10.1371/journal.pmed.1001056 21811403

9. Reynolds LJ, Camlin CS, Ware NC, Seeley J. Exploring critical questions for the implementation of “universal test and treat” approaches to HIV prevention and care. AIDS Care. 2016;28(Suppl 3):1–6. doi: 10.1080/09540121.2016.1178960 27421046

10. AVAC: Global Advocacy for HIV Prevention. Ongoing and planned PrEP demonstration and implementation studies. New York: AVAC: Global Advocacy for HIV Prevention; 2017 October [cited 2017 Nov 1]. Available from: http://www.avac.org/resource/ongoing-and-planned-prep-demonstration-and-implementation-studies.

11. Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated delivery of antiretroviral treatment and pre-exposure prophylaxis to HIV-1–serodiscordant couples: a prospective implementation study in Kenya and Uganda. PLOS Med. 2016;13(8):e1002099. doi: 10.1371/journal.pmed.1002099 27552090

12. Cowan F. Results of the SAPPH-IRe Trial: a cluster randomised trial of a combination intervention to empower female sex workers in Zimbabwe to link and adhere to antiretrovirals for treatment and prevention. 21st International AIDS Conference; 2016 Jul 18–22; Durban, South Africa. Available from: http://programme.aids2016.org/Abstract/Abstract/10619.

13. South African National AIDS Council. National strategic plan on HIV, STIs and TB: 2012–2016. Pretoria: South African National AIDS Council; 2012.

14. South African National AIDS Programme. Let our actions count: South Africa’s national strategic plan for HIV, TB and STIs 2017–2022. Pretoria: South African National AIDS Council; 2017 [cited 2017 Oct 20]. Available from: http://sanac.org.za/wp-content/uploads/2017/05/NSP_FullDocument_FINAL.pdf.

15. South African National AIDS Council. National strategic plan for HIV prevention, care and treatment for sex workers. Pretoria: South African National AIDS Council; 2013.

16. Sibanyoni M. Sex in the cities: comprehensive healthcare for sex workers. 7th SA AIDS Conference; 2015 Jun 9–12; Durban, South Africa.

17. Gomez GB, Eakle R, Mbogua J, Akpomiemie G, Venter WDF, Rees H. Treatment And Prevention for female Sex workers in South Africa: protocol for the TAPS Demonstration Project. BMJ Open. 2016;6:e011595. doi: 10.1136/bmjopen-2016-011595 27678533

18. Eakle R, Manthata G, Stadler J, Mbogua J, Sibanyoni M, Venter WDF, et al. Preparing for PrEP & immediate treatment: focus group discussions in advance of a demonstration project in South Africa. AIDS Res Hum Retroviruses. 2014;30(S1):A269–70. doi: 10.1089/aid.2014.5606.abstract

19. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry E6 good clinical practice: consolidated guidance. Silver Spring (Maryland): US Food and Drug Administration; 1996 [cited 2017 Jul 23]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm073122.pdf.

20. World Health Organization. Adverse drug reactions monitoring. Geneva: World Health Organization; 2017 [cited 2017 Jul 23]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/advdrugreactions/en/

21. Fox MP, Rosen R. Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69:98–108. doi: 10.1097/QAI.0000000000000553 25942461

22. South African National AIDS Council. The South African national sex worker HIV plan, 2016–2019. Pretoria: South African National AIDS Council; 2016 Mar [cited 2017 Oct 20]. Available from: http://southafrica.unfpa.org/publications/south-african-national-sex-worker-hiv-plan-2016-2019.

23. South Africa National Department of Health. Guidelines for expanding combination prevention and treatment options for sex workers: oral pre-exposure prophylaxis (PrEP) and test and treat (T&T). Pretoria: South Africa National Department of Health; 2016 May [cited 2017 Oct 20]. Available from: http://www.sahivsoc.org/Files/PrEP%20and%20TT%20Guidelines%20-%20Final%20Draft%20-%2011%20May%202016.pdf.

24. Myers JE, Sepkowitz KA. A pill for HIV prevention: déjà vu all over again? Clin Infect Dis. 2013;56:1604–12. doi: 10.1093/cid/cit085 23408681

25. May C, Finch T, Mair F, Ballini L, Dowrick C, Eccles M, et al. Understanding the implementation of complex interventions in health care: the normalization process model. BMC Health Serv Res. 2007;7:148. doi: 10.1186/1472-6963-7-148 17880693

26. University of California, San Francisco, Anova Health Institute, Wits Reproductive Health and HIV Institute. South African Health Monitoring Survey (SAHMS): an integrated biological and behavioural survey among female sex workers, South Africa 2013–2014. San Francisco: University of California, San Francisco; 2015.

27. Slabbert M, Venter F, Gay C, Roelofsen C, Lalla-Edward S, Rees H. Sexual and reproductive health outcomes among female sex workers in Johannesburg and Pretoria, South Africa: recommendations for public health programmes. BMC Public Health. 2017;17:17–27. doi: 10.1186/s12889-017-4346-0

28. PrEP: demonstration for implementation. Oral Abstract Session Track C: TUAC02. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2015 Jul 19–22; Vancouver, Canada.

29. Smith JA, Anderson S-J, Harris KL, McGillen JB, Lee E, Garnett GP, et al. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV. 2016;3:e289–96. doi: 10.1016/S2352-3018(16)30036-4 27365203

30. South Africa National Department of Health, South African National AIDS Council. South African HIV and TB investment case: summary report—phase 1. Pretoria: South African National AIDS Council; 2016 Mar [cited 2017 Oct 20]. Available from: http://sanac.org.za/wp-content/uploads/2016/03/1603-Summary-Report-LowRes-18-Mar.pdf.

31. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60. doi: 10.1016/S0140-6736(15)00056-2 26364263